Other Events ·
SciSparc Ltd.'s subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site at the Yale Child Study Center…
SPRCSciSparc Ltd.
SciSparc Ltd.'s subsidiary NeuroThera Labs initiated a Phase IIb clinical trial site at the Yale Child Study Center for SCI-110, a cannabinoid-based drug candidate targeting Tourette Syndrome in adults. The randomized, double-blind study builds on positive Phase IIa results showing a 21% average tic reduction and will evaluate efficacy and safety at sites in the U.S., Germany, and Israel. SciSparc Ltd. operates as a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapeutics for central nervous system disorders.